KLRS

Insider Trades

Name	Value	Action	Price	Current Price
Hagen Brett RChief Accounting Officer $8.1k907 shares SellMar 26, 2025 $8.97 --
Akkaraju SrinivasDirector, 10 Percent Owner: $5.0M479.8k shares BuyDec 18, 2025 $10.42 --
Hagen Brett RChief Accounting Officer $13k1.9k shares SellMar 20, 2026 $6.72 --
Akkaraju SrinivasDirector, 10 Percent Owner: $1.2M244.3k shares BuyMay 20, 2026 $4.83 --

News

globenewswire.comKalaris to Present at Clinical Trials at the Summit 2026globenewswire.comJun 12

globenewswire.comKalaris Reports First Quarter 2026 Financial Results and Provides Business Updatesglobenewswire.comMay 12

Trade KLRS

About Kalaris Therapeutics Inc

Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked diseases, especially in patients with profoundly compromised immune systems.

CEO: Andrew Oxtoby
IPO Date: Jul 30, 2020

Market Data

Open: $4.61
High: $4.80
Low: $4.55
Volume: 165.6K
Avg Volume: 84.5K
52W High: $11.88
52W Low: $2.14

Valuation

Market Cap: $88M
Enterprise Value: $55M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-43M
Revenue: $0
Net Income: $-43M
Cash: $98M
Debt: $1.4M

Events

EarningsAug 12

EPS est. -0.5